GlassScriptPhysician profile
David N Feldman
NPI 1982667317
$335,154.34
in general payments reported to CMS, 2019-2025
33 companies · $94K in 2025
The $94K reported for 2025 was more than what 92% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,933 · 2020: $456 · 2021: $440 · 2022: $46K · 2023: $96K · 2024: $95K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $285K · Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $284,891.02 |
| Food and Beverage | $777.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthopediatrics Corp. | $330,115.95 | 2022-2025 | |
| Smith+Nephew, INC. | $2,093.47 | 2019-2025 | Aetos Shoulder System, Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Seapearl East, INC | $647.94 | 2019 | |
| Depuy Synthes Sales INC. | $477.46 | 2019-2025 | Orthovisc, Monovisc |
| Scilex Pharmaceuticals INC. | $254.21 | 2020-2024 | Ztlido |
| Fidia Pharma USA INC. | $179.89 | 2019-2023 | Hymovis |
| Heraeus Medical, LLC. | $132.48 | 2022-2024 | Palacos |
| Zyla Life Sciences, INC. | $111.11 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $104.31 | 2019-2022 | |
| Almatica Pharma LLC | $102.43 | 2021 | |
| Horizon Therapeutics Plc | $97.97 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $68.93 | 2022-2023 | Seglentis |
| Ferring Pharmaceuticals INC. | $68.00 | 2024 | Euflexxa |
| Azurity Pharmaceuticals, INC. | $64.05 | 2023-2024 | Horizant, Horizant |
| Avanos Medical | $61.01 | 2022-2024 | Trivisc Sodium Hyaluronate |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $54.61 | 2019 | |
| Davol INC. | $51.40 | 2021 | |
| Arbor Pharmaceuticals, INC. | $46.47 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.29 | 2024 | Xifaxan |
| Stryker Corporation | $43.18 | 2019 | |
| Ibsa Pharma INC. | $41.68 | 2023-2024 | Tirosint, Licart, Tirosint |
| Convatec INC. | $36.71 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $35.59 | 2024-2025 | |
| Zimvie INC. | $32.52 | 2022 | |
| Paragon 28, INC. | $29.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.45 | 2019-2021 | |
| Heron Therapeutics, INC. | $29.31 | 2021 | |
| Djo, LLC | $23.40 | 2024 | Donjoy |
| Innovation Technologies INC | $19.13 | 2025 | Irrisept |
| Bioventus LLC | $18.02 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.48 | 2021 | |
| Assertio Therapeutics, INC. | $13.16 | 2020 | |
| Ermi LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.